Details of the Drug Combinations

General Information of This Drug (ID: DM3A701)

Drug Name
IDP-122   DM3A701
Indication
Disease Entry ICD 11 Status REF
Exanthem N.A. Approved [1]
Granuloma annulare N.A. Approved [1]
Primary cutaneous T-cell lymphoma N.A. Approved [1]
Plaque psoriasis EA90.0 Phase 3 [2]

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Tazarotene + IDP-122 DC40DIQ Tazarotene Psoriasis Vulgaris [3]
------------------------------------------------------------------------------------

References

1 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT06042647) Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis